Utilization of lipid lowering medications among adults in the United States 1999-2006

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 456-460

  Li, Mingfang ^a   Ong, Kwok Leung ^a   Tse, Hung Fat ^a   Cheung, Bernard M Y ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Coronary heart disease; Diabetes; Dyslipidemia; Lipid lowering medication; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLESVELAM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVANIACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROBUCOL; ROVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ETHNICITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RELIABILITY; RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK; TIME FACTORS; UNITED STATES;

EID: 74749095536     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.001     Document Type: Article

References (24)

1. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
3. Cheung B.M.Y., Lauder I.J., Lau C.P., and Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57 (2004) 640-651
4. Brown M.S., and Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21 (1980) 505-517
5. Bilheimer D.W., Grundy S.M., Brown M.S., and Goldstein J.L. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Phys 96 (1983) 1-9
6. Pahan K. Lipid-lowering drugs. Cell Mol Life Sci 63 (2006) 1165-1178
7. Watts G.F., and Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10 (1999) 561-574
8. Insull Jr. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99 (2006) 257-273
9. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
10. National Center for Health Statistics. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed October 11, 2008.
11. Hyre A.D., Muntner P., Menke A., Raggi P., and He J. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 17 (2007) 548-555
12. Keevil J.G., Cullen M.W., Gangnon R., McBride P.E., and Stein J.H. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 115 (2007) 1363-1370
13. Cullen M.W., Stein J.H., Gangnon R., McBride P.E., and Keevil J.G. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart J 156 (2008) 284-291
14. Ghandehari H., Kamal-Bahl S., and Wong N.D. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 156 (2008) 112-119
15. Mann D., Reynolds K., Smith D., and Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42 (2008) 1208-1215
16. Blair S.N., Smith S.C., and Allen J. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372
17. Voelker R. Widespread statin use recommended for patients with type 2 diabetes. JAMA 291 (2004) 2419-2420
18. Carroll M.D., Lacher D.A., Sorlie P.D., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
19. Arnett D.K., Jacobs D.R., Luepker R.V., et al. Twenty years trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use. The Minnesota Heart Survey 1980-82 to 2000-02. Circulation 112 (2005) 3884-3891
20. Haffner S.M., Alexander T.J., Cook S.J., et al. Reduced cardiovascular events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
21. Pyörälä K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
22. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98 (1998) 2513-2519
23. Thavendiranathan P., Bagai A., Brookhart M.A., and Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 2307-2313
24. Mills E.J., Rachlis B., Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 25 52 (2008) 1769-1781